Roger L. Albin - Publications

Affiliations: 
University of Michigan, Ann Arbor, Ann Arbor, MI 
Area:
Basal Ganglia

153 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Zhou Z, Müller MLTM, Kanel P, Chua J, Kotagal V, Kaufer DI, Albin RL, Frey KA, Bohnen NI. Apathy rating scores and β-amyloidopathy in Parkinson disease patients at risk for cognitive decline. Neurology. PMID 31732566 DOI: 10.1212/Wnl.0000000000008683  0.303
2018 Tang X, Ross CA, Johnson H, Paulsen JS, Younes L, Albin RL, Ratnanather JT, Miller MI. Regional subcortical shape analysis in premanifest Huntington's disease. Human Brain Mapping. PMID 30376191 DOI: 10.1002/Hbm.24456  0.333
2018 Bohnen NI, Albin RL. Hypercholinergic activity in LRRK2 Parkinson's disease. The Lancet. Neurology. PMID 29456160 DOI: 10.1016/S1474-4422(18)30073-5  0.323
2017 Albin RL, Leventhal DK. The Missing, The Short, and The Long: L-Dopa Responses and Dopamine Actions. Annals of Neurology. PMID 28543679 DOI: 10.1002/Ana.24961  0.303
2017 Albin RL. What would Dr. James Parkinson think today? II. Neuroimaging in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 32: 179-180. PMID 28218459 DOI: 10.1002/mds.26951  0.321
2017 Kotagal V, Bohnen NI, Müller ML, Frey KA, Albin RL. Cerebral Amyloid Burden and Hoehn and Yahr Stage 3 Scoring in Parkinson Disease. Journal of Parkinson's Disease. PMID 28106566 DOI: 10.3233/Jpd-160985  0.312
2016 Ridder A, Müller ML, Kotagal V, Frey KA, Albin RL, Bohnen NI. Impaired contrast sensitivity is associated with more severe cognitive impairment in Parkinson disease. Parkinsonism & Related Disorders. 34: 15-19. PMID 27742131 DOI: 10.1016/J.Parkreldis.2016.10.006  0.307
2016 Kotagal V, Lineback C, Bohnen NI, Albin RL. Orthostatic hypotension predicts motor decline in early Parkinson disease. Parkinsonism & Related Disorders. PMID 27639815 DOI: 10.1016/j.parkreldis.2016.09.011  0.326
2016 Albin RL, Frey KA. Reverse Translation in Parkinson Disease. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27151982 DOI: 10.2967/Jnumed.116.175257  0.334
2016 Haugen J, Müller ML, Kotagal V, Albin RL, Koeppe RA, Scott PJ, Frey KA, Bohnen NI. Prevalence of impaired odor identification in Parkinson disease with imaging evidence of nigrostriatal denervation. Journal of Neural Transmission (Vienna, Austria : 1996). PMID 26911386 DOI: 10.1007/S00702-016-1524-7  0.3
2016 Kumar A, Zhang J, Tallaksen-Greene S, Crowley MR, Crossman DK, Morton AJ, van Groen T, Kadish I, Albin RL, Lesort M, Detloff PJ. Allelic Series of Huntington's Disease Knock-in Mice Reveals Expression Discorrelates. Human Molecular Genetics. PMID 26908599 DOI: 10.1093/Hmg/Ddw040  0.331
2016 Petrou M, Davatzikos C, Hsieh M, Foerster BR, Albin RL, Kotagal V, Müller ML, Koeppe RA, Herman WH, Frey KA, Bohnen NI. Diabetes, Gray Matter Loss, and Cognition in the Setting of Parkinson Disease. Academic Radiology. PMID 26874576 DOI: 10.1016/J.Acra.2015.07.014  0.304
2015 Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, ... ... Albin R, et al. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. Jama Neurology. 1-9. PMID 26569098 DOI: 10.1001/Jamaneurol.2015.2736  0.65
2015 Albin RL, Miller RA. Mini-review: Retarding aging in murine genetic models of neurodegeneration. Neurobiology of Disease. 85: 73-80. PMID 26477301 DOI: 10.1016/j.nbd.2015.10.014  0.302
2015 Albin RL, Burke JF. Potential trade-offs in treatment of premanifest Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1319-23. PMID 26173644 DOI: 10.1002/mds.26318  0.308
2015 Zeng L, Wang B, Merillat SA, Minakawa E, Perkins MD, Ramani B, Tallaksen-Greene SJ, Costa MD, Albin RL, Paulson HL. Differential recruitment of UBQLN2 to nuclear inclusions in the polyglutamine diseases HD and SCA3. Neurobiology of Disease. PMID 26141599 DOI: 10.1016/j.nbd.2015.06.017  0.341
2015 Kotagal V, Bohnen NI, Müller ML, Koeppe RA, Frey KA, Langa KM, Albin RL. Educational attainment and motor burden in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 1143-7. PMID 26096339 DOI: 10.1002/Mds.26272  0.302
2015 Müller ML, Albin RL, Bohnen NI, Jennings D, Siderowf A, Stern M, Seibyl J, Eberly S, Oakes D, Marek K. Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study. Neurology. 84: 2292. PMID 26033339 DOI: 10.1212/Wnl.0000000000001654  0.306
2015 Petrou M, Dwamena BA, Foerster BR, MacEachern MP, Bohnen NI, Müller ML, Albin RL, Frey KA. Amyloid deposition in Parkinson's disease and cognitive impairment: A systematic review. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 928-35. PMID 25879534 DOI: 10.1002/Mds.26191  0.334
2015 Kucinski A, Albin RL, Lustig C, Sarter M. Modeling falls in Parkinson's disease: Slow gait, freezing episodes and falls in rats with extensive striatal dopamine loss. Behavioural Brain Research. 282: 155-64. PMID 25595423 DOI: 10.1016/j.bbr.2015.01.012  0.338
2015 Bohnen NI, Albin RL, Müller ML, Petrou M, Kotagal V, Koeppe RA, Scott PJ, Frey KA. Frequency of cholinergic and caudate nucleus dopaminergic deficits across the predemented cognitive spectrum of Parkinson disease and evidence of interaction effects. Jama Neurology. 72: 194-200. PMID 25506674 DOI: 10.1001/Jamaneurol.2014.2757  0.327
2015 Dayalu P, Albin RL. Huntington disease: pathogenesis and treatment. Neurologic Clinics. 33: 101-14. PMID 25432725 DOI: 10.1016/j.ncl.2014.09.003  0.327
2015 Müller ML, Bohnen NI, Kotagal V, Scott PJ, Koeppe RA, Frey KA, Albin RL. Clinical markers for identifying cholinergic deficits in Parkinson's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 30: 269-73. PMID 25393613 DOI: 10.1002/Mds.26061  0.319
2014 Bohnen NI, Müller MLTM, Dauer WT, Albin RL. Parkinson's Disease: What role do pedunculopontine nucleus cholinergic neurons play? Future Neurology. 9: 5-8. PMID 28845134 DOI: 10.2217/fnl.13.61  0.363
2014 Tallaksen-Greene SJ, Sadagurski M, Zeng L, Mauch R, Perkins M, Banduseela VC, Lieberman AP, Miller RA, Paulson HL, Albin RL. Differential effects of delayed aging on phenotype and striatal pathology in a murine model of Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 34: 15658-68. PMID 25411494 DOI: 10.1523/JNEUROSCI.1830-14.2014  0.358
2014 Pappas SS, Leventhal DK, Albin RL, Dauer WT. Mouse models of neurodevelopmental disease of the basal ganglia and associated circuits. Current Topics in Developmental Biology. 109: 97-169. PMID 24947237 DOI: 10.1016/B978-0-12-397920-9.00001-9  0.362
2014 Bohnen NI, Frey KA, Studenski S, Kotagal V, Koeppe RA, Constantine GM, Scott PJ, Albin RL, Müller ML. Extra-nigral pathological conditions are common in Parkinson's disease with freezing of gait: an in vivo positron emission tomography study. Movement Disorders : Official Journal of the Movement Disorder Society. 29: 1118-24. PMID 24909584 DOI: 10.1002/Mds.25929  0.346
2014 Fawaz MV, Brooks AF, Rodnick ME, Carpenter GM, Shao X, Desmond TJ, Sherman P, Quesada CA, Hockley BG, Kilbourn MR, Albin RL, Frey KA, Scott PJ. High affinity radiopharmaceuticals based upon lansoprazole for PET imaging of aggregated tau in Alzheimer's disease and progressive supranuclear palsy: synthesis, preclinical evaluation, and lead selection. Acs Chemical Neuroscience. 5: 718-30. PMID 24896980 DOI: 10.1021/Cn500103U  0.316
2014 Kotagal V, Albin RL, Müller ML, Koeppe RA, Studenski S, Frey KA, Bohnen NI. Advanced age, cardiovascular risk burden, and timed up and go test performance in Parkinson disease. The Journals of Gerontology. Series a, Biological Sciences and Medical Sciences. 69: 1569-75. PMID 24864306 DOI: 10.1093/Gerona/Glu070  0.325
2014 Sarter M, Albin RL, Kucinski A, Lustig C. Where attention falls: Increased risk of falls from the converging impact of cortical cholinergic and midbrain dopamine loss on striatal function. Experimental Neurology. 257: 120-9. PMID 24805070 DOI: 10.1016/j.expneurol.2014.04.032  0.346
2014 Mehanna R, Bohnen N, Sarter M, Muller M, Dauer W, Albin R, Arbor A. Gait speed in Parkinson disease correlates with cholinergic degenerationAuthor Response Neurology. 82: 1568-1569. PMID 24778286 DOI: 10.1212/01.Wnl.0000446971.02565.F1  0.326
2014 Albin RL, Dauer WT. Magic shotgun for Parkinson's disease? Brain : a Journal of Neurology. 137: 1274-5. PMID 24771397 DOI: 10.1093/brain/awu076  0.328
2014 Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI. Modifiable cardiovascular risk factors and axial motor impairments in Parkinson disease. Neurology. 82: 1514-20. PMID 24682965 DOI: 10.1212/Wnl.0000000000000356  0.308
2014 Younes L, Ratnanather JT, Brown T, Aylward E, Nopoulos P, Johnson H, Magnotta VA, Paulsen JS, Margolis RL, Albin RL, Miller MI, Ross CA. Regionally selective atrophy of subcortical structures in prodromal HD as revealed by statistical shape analysis. Human Brain Mapping. 35: 792-809. PMID 23281100 DOI: 10.1002/Hbm.22214  0.317
2013 Zeng L, Tallaksen-Greene SJ, Wang B, Albin RL, Paulson HL. The de-ubiquitinating enzyme ataxin-3 does not modulate disease progression in a knock-in mouse model of Huntington disease. Journal of Huntington's Disease. 2: 201-15. PMID 24683430 DOI: 10.3233/JHD-130058  0.39
2013 Stutzbach LD, Xie SX, Naj AC, Albin R, Gilman S, Lee VM, Trojanowski JQ, Devlin B, Schellenberg GD. The unfolded protein response is activated in disease-affected brain regions in progressive supranuclear palsy and Alzheimer's disease. Acta Neuropathologica Communications. 1: 31. PMID 24252572 DOI: 10.1186/2051-5960-1-31  0.519
2013 Bohnen NI, Frey KA, Studenski S, Kotagal V, Koeppe RA, Scott PJ, Albin RL, Müller ML. Gait speed in Parkinson disease correlates with cholinergic degeneration. Neurology. 81: 1611-6. PMID 24078735 DOI: 10.1212/Wnl.0B013E3182A9F558  0.303
2013 Müller ML, Albin RL, Kotagal V, Koeppe RA, Scott PJ, Frey KA, Bohnen NI. Thalamic cholinergic innervation and postural sensory integration function in Parkinson's disease. Brain : a Journal of Neurology. 136: 3282-9. PMID 24056537 DOI: 10.1093/Brain/Awt247  0.367
2013 Albin RL, Burke JF, Koeppe RA, Giordani B, Gilman S, Frey KA. Assessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 887-93. PMID 23572495 DOI: 10.2967/Jnumed.112.112599  0.485
2013 Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI. Gender differences in cholinergic and dopaminergic deficits in Parkinson disease. Journal of Neural Transmission (Vienna, Austria : 1996). 120: 1421-4. PMID 23532360 DOI: 10.1007/S00702-013-1013-1  0.318
2013 Kotagal V, Albin RL, Müller ML, Koeppe RA, Frey KA, Bohnen NI. Diabetes is associated with postural instability and gait difficulty in Parkinson disease. Parkinsonism & Related Disorders. 19: 522-6. PMID 23462483 DOI: 10.1016/J.Parkreldis.2013.01.016  0.319
2013 Müller ML, Frey KA, Petrou M, Kotagal V, Koeppe RA, Albin RL, Bohnen NI. β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. Movement Disorders : Official Journal of the Movement Disorder Society. 28: 296-301. PMID 23239424 DOI: 10.1002/Mds.25213  0.347
2012 Kotagal V, Bohnen NI, Müller ML, Koeppe RA, Frey KA, Albin RL. Cerebral amyloid deposition and serotoninergic innervation in Parkinson disease. Archives of Neurology. 69: 1628-31. PMID 22964894 DOI: 10.1001/Archneurol.2012.764  0.342
2012 Petrou M, Bohnen NI, Müller ML, Koeppe RA, Albin RL, Frey KA. Aβ-amyloid deposition in patients with Parkinson disease at risk for development of dementia. Neurology. 79: 1161-7. PMID 22933741 DOI: 10.1212/Wnl.0B013E3182698D4A  0.329
2012 Lelieveld IM, Müller ML, Bohnen NI, Koeppe RA, Chervin RD, Frey KA, Albin RL. The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C]DASB PET imaging study. Plos One. 7: e40166. PMID 22792235 DOI: 10.1371/Journal.Pone.0040166  0.321
2012 Albin RL, Dauer WT. Parkinson syndrome. Heterogeneity of etiology; heterogeneity of pathogenesis? Neurology. 79: 202-3. PMID 22722622 DOI: 10.1212/WNL.0b013e31825dd3d0  0.334
2012 Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MR, Gilman S, Albin RL, Frey KA. Heterogeneity of cholinergic denervation in Parkinson's disease without dementia. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 32: 1609-17. PMID 22569194 DOI: 10.1038/Jcbfm.2012.60  0.508
2012 Coppola G, Chinnathambi S, Lee JJ, Dombroski BA, Baker MC, Soto-Ortolaza AI, Lee SE, Klein E, Huang AY, Sears R, Lane JR, Karydas AM, Kenet RO, Biernat J, Wang LS, ... ... Albin RL, et al. Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Human Molecular Genetics. 21: 3500-12. PMID 22556362 DOI: 10.1093/Hmg/Dds161  0.322
2012 Kotagal V, Albin RL, Müller ML, Koeppe RA, Chervin RD, Frey KA, Bohnen NI. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Annals of Neurology. 71: 560-8. PMID 22522445 DOI: 10.1002/Ana.22691  0.337
2012 Bohnen N, Albin R, Kotagal V, Frey K, Muller M. Decreased Vestibular Efficacy Contributes To Balance Impairment in Parkinson Disease (PD4.009) Neurology. 78: PD4.009-PD4.009. DOI: 10.1212/Wnl.78.1_Meetingabstracts.Pd4.009  0.315
2012 Bly B, Muller M, Albin R, Frey K, Bohnen N. The Prevalence of Impaired Olfaction in Parkinson's Disease Is Higher Than Previously Estimated (P07.129) Neurology. 78: P07.129-P07.129. DOI: 10.1212/Wnl.78.1_Meetingabstracts.P07.129  0.303
2012 Ghetti B, Murrell J, Koeppe R, Gilman S, Fink J, Miravalle L, Albin R, Vidal R, Foster N. Follow-up of the first American report of familial Alzheimer's disease Alzheimers & Dementia. 8: 665. DOI: 10.1016/J.Jalz.2012.05.1793  0.468
2011 Tallaksen-Greene SJ, Albin RL. Treating mouse models of Huntington disease. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 2373-4. PMID 21814186 DOI: 10.1038/npp.2011.158  0.323
2011 Bohnen NI, Müller ML, Zarzhevsky N, Koeppe RA, Bogan CW, Kilbourn MR, Frey KA, Albin RL. Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease. Brain : a Journal of Neurology. 134: 2358-65. PMID 21653540 DOI: 10.1093/Brain/Awr139  0.343
2011 Bohnen NI, Koeppe RA, Minoshima S, Giordani B, Albin RL, Frey KA, Kuhl DE. Cerebral glucose metabolic features of Parkinson disease and incident dementia: longitudinal study. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 52: 848-55. PMID 21571793 DOI: 10.2967/Jnumed.111.089946  0.309
2011 Burke JF, Albin RL, Koeppe RA, Giordani B, Kilbourn MR, Gilman S, Frey KA. Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography. Brain : a Journal of Neurology. 134: 1647-57. PMID 21555336 DOI: 10.1093/Brain/Awr089  0.487
2011 Bohnen NI, Albin RL. White matter lesions in Parkinson disease. Nature Reviews. Neurology. 7: 229-36. PMID 21343896 DOI: 10.1038/nrneurol.2011.21  0.325
2011 Bohnen NI, Albin RL. The cholinergic system and Parkinson disease. Behavioural Brain Research. 221: 564-73. PMID 20060022 DOI: 10.1016/j.bbr.2009.12.048  0.376
2011 Gilman S, Giordani B, Albin R, Koeppe R, Burke J, Kilbourn M, Frey K. Mild Dementia evaluated with [11C]DTBZ and [11C]PiB positron emission tomography Alzheimers & Dementia. 7. DOI: 10.1016/J.Jalz.2011.05.277  0.429
2010 Heng MY, Detloff PJ, Paulson HL, Albin RL. Early alterations of autophagy in Huntington disease-like mice. Autophagy. 6: 1206-8. PMID 20935460 DOI: 10.4161/Auto.6.8.13617  0.773
2010 Tallaksen-Greene SJ, Janiszewska A, Benton K, Ruprecht L, Albin RL. Lack of efficacy of NMDA receptor-NR2B selective antagonists in the R6/2 model of Huntington disease. Experimental Neurology. 225: 402-7. PMID 20659453 DOI: 10.1016/j.expneurol.2010.07.015  0.336
2010 Heng MY, Duong DK, Albin RL, Tallaksen-Greene SJ, Hunter JM, Lesort MJ, Osmand A, Paulson HL, Detloff PJ. Early autophagic response in a novel knock-in model of Huntington disease. Human Molecular Genetics. 19: 3702-20. PMID 20616151 DOI: 10.1093/Hmg/Ddq285  0.778
2010 Perry GM, Tallaksen-Greene S, Kumar A, Heng MY, Kneynsberg A, van Groen T, Detloff PJ, Albin RL, Lesort M. Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease. Human Molecular Genetics. 19: 3354-71. PMID 20558522 DOI: 10.1093/Hmg/Ddq247  0.749
2010 Bohnen NI, Müller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, Frey KA. Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson's disease. Brain : a Journal of Neurology. 133: 1747-54. PMID 20413575 DOI: 10.1093/Brain/Awq079  0.366
2010 Albin RL, Koeppe RA, Burke JF, Giordani B, Kilbourn MR, Gilman S, Frey KA. Comparing fludeoxyglucose F18-PET assessment of regional cerebral glucose metabolism and [11C]dihydrotetrabenazine-PET in evaluation of early dementia and mild cognitive impairment. Archives of Neurology. 67: 440-6. PMID 20385910 DOI: 10.1001/Archneurol.2010.34  0.45
2010 Hwang H, Zhang J, Chung KA, Leverenz JB, Zabetian CP, Peskind ER, Jankovic J, Su Z, Hancock AM, Pan C, Montine TJ, Pan S, Nutt J, Albin R, Gearing M, et al. Glycoproteomics in neurodegenerative diseases. Mass Spectrometry Reviews. 29: 79-125. PMID 19358229 DOI: 10.1002/Mas.20221  0.33
2009 Bohnen NI, Müller ML, Koeppe RA, Studenski SA, Kilbourn MA, Frey KA, Albin RL. History of falls in Parkinson disease is associated with reduced cholinergic activity. Neurology. 73: 1670-6. PMID 19917989 DOI: 10.1212/Wnl.0B013E3181C1Ded6  0.321
2009 Bohnen NI, Albin RL. Cholinergic denervation occurs early in Parkinson disease. Neurology. 73: 256-7. PMID 19535769 DOI: 10.1212/WNL.0b013e3181b0bd3d  0.368
2009 Tallaksen-Greene SJ, Janiszewska A, Benton K, Hou G, Dick R, Brewer GJ, Albin RL. Evaluation of tetrathiomolybdate in the R6/2 model of Huntington disease. Neuroscience Letters. 452: 60-2. PMID 19429000 DOI: 10.1016/J.Neulet.2009.01.040  0.353
2009 Albin RL, Koeppe RA, Wernette K, Zhuang W, Nichols T, Kilbourn MR, Frey KA. Striatal [11C]dihydrotetrabenazine and [11C]methylphenidate binding in Tourette syndrome. Neurology. 72: 1390-6. PMID 19380698 DOI: 10.1212/Wnl.0B013E3181A187Dd  0.31
2009 Heng MY, Detloff PJ, Wang PL, Tsien JZ, Albin RL. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 29: 3200-5. PMID 19279257 DOI: 10.1523/Jneurosci.5599-08.2009  0.774
2008 Kitsou E, Pan S, Zhang J, Shi M, Zabeti A, Dickson DW, Albin R, Gearing M, Kashima DT, Wang Y, Beyer RP, Zhou Y, Pan C, Caudle WM, Zhang J. Identification of proteins in human substantia nigra. Proteomics. Clinical Applications. 2: 776-82. PMID 21136874 DOI: 10.1002/Prca.200800028  0.305
2008 Heng MY, Detloff PJ, Albin RL. Rodent genetic models of Huntington disease. Neurobiology of Disease. 32: 1-9. PMID 18638556 DOI: 10.1016/J.Nbd.2008.06.005  0.761
2008 Shi M, Jin J, Wang Y, Beyer RP, Kitsou E, Albin RL, Gearing M, Pan C, Zhang J. Mortalin: a protein associated with progression of Parkinson disease? Journal of Neuropathology and Experimental Neurology. 67: 117-24. PMID 18219256 DOI: 10.1097/Nen.0B013E318163354A  0.312
2008 Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson's disease. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 28: 441-4. PMID 18073772 DOI: 10.1038/Sj.Jcbfm.9600599  0.346
2008 McKinney BC, Schneider JS, Schafer GL, Lowing JL, Mohan S, Zhao MX, Heng MY, Albin RL, Seasholtz AF, Akil H, Murphy GG. Decreased locomotor activity in mice expressing tTA under control of the CaMKII alpha promoter. Genes, Brain, and Behavior. 7: 203-13. PMID 17640289 DOI: 10.1111/J.1601-183X.2007.00339.X  0.732
2007 Heng MY, Tallaksen-Greene SJ, Detloff PJ, Albin RL. Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 8989-98. PMID 17715336 DOI: 10.1523/Jneurosci.1830-07.2007  0.782
2007 Kuhn A, Goldstein DR, Hodges A, Strand AD, Sengstag T, Kooperberg C, Becanovic K, Pouladi MA, Sathasivam K, Cha JH, Hannan AJ, Hayden MR, Leavitt BR, Dunnett SB, Ferrante RJ, ... Albin R, et al. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Human Molecular Genetics. 16: 1845-61. PMID 17519223 DOI: 10.1093/Hmg/Ddm133  0.336
2006 Zhukareva V, Joyce S, Schuck T, Van Deerlin V, Hurtig H, Albin R, Gilman S, Chin S, Miller B, Trojanowski JQ, Lee VM. Unexpected abundance of pathological tau in progressive supranuclear palsy white matter. Annals of Neurology. 60: 335-45. PMID 16823854 DOI: 10.1002/Ana.20916  0.464
2006 Bohnen NI, Albin RL, Koeppe RA, Wernette KA, Kilbourn MR, Minoshima S, Frey KA. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. 26: 1198-212. PMID 16421508 DOI: 10.1038/Sj.Jcbfm.9600276  0.337
2006 Yu Z, Dadgar N, Albertelli M, Scheller A, Albin RL, Robins DM, Lieberman AP. Abnormalities of germ cell maturation and sertoli cell cytoskeleton in androgen receptor 113 CAG knock-in mice reveal toxic effects of the mutant protein. The American Journal of Pathology. 168: 195-204. PMID 16400023 DOI: 10.2353/Ajpath.2006.050619  0.357
2005 Koeppe RA, Gilman S, Joshi A, Liu S, Little R, Junck L, Heumann M, Frey KA, Albin RL. 11C-DTBZ and 18F-FDG PET measures in differentiating dementias. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 46: 936-44. PMID 15937303  0.365
2005 Philips ST, Albin RL, Martin DM. Genetics of subthalamic nucleus in development and disease. Experimental Neurology. 192: 320-30. PMID 15755549 DOI: 10.1016/J.Expneurol.2004.11.008  0.327
2005 Tallaksen-Greene SJ, Crouse AB, Hunter JM, Detloff PJ, Albin RL. Neuronal intranuclear inclusions and neuropil aggregates in HdhCAG(150) knockin mice. Neuroscience. 131: 843-52. PMID 15749339 DOI: 10.1016/J.Neuroscience.2004.10.037  0.362
2005 Ravina B, Eidelberg D, Ahlskog JE, Albin RL, Brooks DJ, Carbon M, Dhawan V, Feigin A, Fahn S, Guttman M, Gwinn-Hardy K, McFarland H, Innis R, Katz RG, Kieburtz K, et al. The role of radiotracer imaging in Parkinson disease. Neurology. 64: 208-15. PMID 15668415 DOI: 10.1212/01.Wnl.0000149403.14458.7F  0.313
2004 Deng YP, Albin RL, Penney JB, Young AB, Anderson KD, Reiner A. Differential loss of striatal projection systems in Huntington's disease: a quantitative immunohistochemical study. Journal of Chemical Neuroanatomy. 27: 143-64. PMID 15183201 DOI: 10.1016/j.jchemneu.2004.02.005  0.504
2004 Lorincz MT, Detloff PJ, Albin RL, O'Shea KS. Embryonic stem cells expressing expanded CAG repeats undergo aberrant neuronal differentiation and have persistent Oct-4 and REST/NRSF expression. Molecular and Cellular Neurosciences. 26: 135-43. PMID 15121185 DOI: 10.1016/j.mcn.2004.01.016  0.323
2004 Montgomery EB, Pan T, Le W, Jankovic J, Ahlskog JE, Wooten GF, Albin RL, Frey KA. Slowing Parkinson's disease progression: Recent dopamine agonist trials [3] (multiple letters) Neurology. 62: 343-345. DOI: 10.1212/Wnl.62.2.343  0.331
2003 Feeley Kearney JA, Albin RL. mGluRs: a target for pharmacotherapy in Parkinson disease. Experimental Neurology. 184: S30-6. PMID 14597323 DOI: 10.1016/S0014-4886(03)00391-1  0.315
2003 Tallaksen-Greene SJ, Ordway JM, Crouse AB, Jackson WS, Detloff PJ, Albin RL. Hprt(CAG)146 mice: age of onset of behavioral abnormalities, time course of neuronal intranuclear inclusion accumulation, neurotransmitter marker alterations, mitochondrial function markers, and susceptibility to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. The Journal of Comparative Neurology. 465: 205-19. PMID 12949782 DOI: 10.1002/Cne.10855  0.368
2003 Albin RL, Koeppe RA, Bohnen NI, Nichols TE, Meyer P, Wernette K, Minoshima S, Kilbourn MR, Frey KA. Increased ventral striatal monoaminergic innervation in Tourette syndrome. Neurology. 61: 310-5. PMID 12913189 DOI: 10.1212/01.Wnl.0000076181.39162.Fc  0.318
2003 Albin RL. Dominant ataxias and Friedreich ataxia: an update. Current Opinion in Neurology. 16: 507-14. PMID 12869811 DOI: 10.1097/01.wco.0000084230.82329.d5  0.317
2003 Jackson WS, Tallaksen-Greene SJ, Albin RL, Detloff PJ. Nucleocytoplasmic transport signals affect the age at onset of abnormalities in knock-in mice expressing polyglutamine within an ectopic protein context. Human Molecular Genetics. 12: 1621-9. PMID 12812988 DOI: 10.1093/Hmg/Ddg163  0.315
2003 Albin RL, Cross D, Cornblath WT, Wald JA, Wernette K, Frey KA, Minoshima S. Diminished striatal [123I]iodobenzovesamicol binding in idiopathic cervical dystonia. Annals of Neurology. 53: 528-32. PMID 12666122 DOI: 10.1002/Ana.10527  0.308
2002 Suzuki M, Desmond TJ, Albin RL, Frey KA. Striatal monoaminergic terminals in Lewy body and Alzheimer's dementias. Annals of Neurology. 51: 767-71. PMID 12112084 DOI: 10.1002/Ana.10186  0.341
2002 Lavedan C, Buchholtz S, Nussbaum RL, Albin RL, Polymeropoulos MH. A mutation in the human neurofilament M gene in Parkinson's disease that suggests a role for the cytoskeleton in neuronal degeneration. Neuroscience Letters. 322: 57-61. PMID 11958843 DOI: 10.1016/S0304-3940(01)02513-7  0.357
2002 Suzuki M, Desmond TJ, Albin RL, Frey KA. Cholinergic vesicular transporters in progressive supranuclear palsy. Neurology. 58: 1013-8. PMID 11940684 DOI: 10.1212/Wnl.58.7.1013  0.345
2001 Suzuki M, Desmond TJ, Albin RL, Frey KA. Vesicular neurotransmitter transporters in Huntington's disease: initial observations and comparison with traditional synaptic markers. Synapse (New York, N.Y.). 41: 329-36. PMID 11494403 DOI: 10.1002/Syn.1089  0.366
2001 Albin RL. End of lines and boxes. Movement Disorders : Official Journal of the Movement Disorder Society. 16: 405-6. PMID 11391733 DOI: 10.1002/mds.1086  0.319
2001 Lin CH, Tallaksen-Greene S, Chien WM, Cearley JA, Jackson WS, Crouse AB, Ren S, Li XJ, Albin RL, Detloff PJ. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Human Molecular Genetics. 10: 137-44. PMID 11152661 DOI: 10.1093/Hmg/10.2.137  0.386
2000 Albin RL. Basal ganglia neurotoxins. Neurologic Clinics. 18: 665-80. PMID 10873237 DOI: 10.1016/S0733-8619(05)70217-6  0.316
2000 Bohnen NI, Koeppe RA, Meyer P, Ficaro E, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL. Decreased striatal monoaminergic terminals in Huntington disease. Neurology. 54: 1753-9. PMID 10802780 DOI: 10.1212/Wnl.54.9.1753  0.355
1999 Dickson DW, Liu W, Hardy J, Farrer M, Mehta N, Uitti R, Mark M, Zimmerman T, Golbe L, Sage J, Sima A, D'Amato C, Albin R, Gilman S, Yen SH. Widespread alterations of alpha-synuclein in multiple system atrophy. The American Journal of Pathology. 155: 1241-51. PMID 10514406 DOI: 10.1016/S0002-9440(10)65226-1  0.454
1999 Meyer P, Bohnen NI, Minoshima S, Koeppe RA, Wernette K, Kilbourn MR, Kuhl DE, Frey KA, Albin RL. Striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome. Neurology. 53: 371-4. PMID 10430428 DOI: 10.1212/Wnl.53.2.371  0.341
1999 Bohnen NI, Albin RL, Frey KA, Fink JK. (+)-alpha-[11C]Dihydrotetrabenazine PET imaging in familial paroxysmal dystonic choreoathetosis. Neurology. 52: 1067-9. PMID 10102431 DOI: 10.1212/Wnl.52.5.1067  0.306
1999 Pennell PB, Burdette DE, Ross DA, Henry TR, Albin RL, Sackellares JC, Frey KA. Muscarinic receptor loss and preservation of presynaptic cholinergic terminals in hippocampal sclerosis. Epilepsia. 40: 38-46. PMID 9924900 DOI: 10.1111/J.1528-1157.1999.Tb01986.X  0.317
1998 Kearney JA, Becker JB, Frey KA, Albin RL. The role of nigrostriatal dopamine in metabotropic glutamate agonist-induced rotation. Neuroscience. 87: 881-91. PMID 9759976 DOI: 10.1016/S0306-4522(98)00193-6  0.302
1998 Tallaksen-Greene SJ, Kaatz KW, Romano C, Albin RL. Localization of mGluR1a-like immunoreactivity and mGluR5-like immunoreactivity in identified populations of striatal neurons. Brain Research. 780: 210-7. PMID 9507137 DOI: 10.1016/S0006-8993(97)01141-4  0.319
1997 Ordway JM, Tallaksen-Greene S, Gutekunst CA, Bernstein EM, Cearley JA, Wiener HW, Dure LS, Lindsey R, Hersch SM, Jope RS, Albin RL, Detloff PJ. Ectopically expressed CAG repeats cause intranuclear inclusions and a progressive late onset neurological phenotype in the mouse. Cell. 91: 753-63. PMID 9413985 DOI: 10.1016/S0092-8674(00)80464-X  0.319
1996 Frey KA, Koeppe RA, Kilbourn MR, Vander Borght TM, Albin RL, Gilman S, Kuhl DE. Presynaptic monoaminergic vesicles in Parkinson's disease and normal aging. Annals of Neurology. 40: 873-84. PMID 9007092 DOI: 10.1002/Ana.410400609  0.529
1996 Tallaksen-Greene SJ, Albin RL. Splice variants of glutamate receptor subunits 2 and 3 in striatal projection neurons. Neuroscience. 75: 1057-64. PMID 8938741 DOI: 10.1016/0306-4522(96)00337-5  0.321
1996 Kaatz KW, Albin RL. Intraseptal administration of (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid induces immediate early gene expression in lateral septal neurons. Brain Research. 709: 205-14. PMID 8833756 DOI: 10.1016/0006-8993(95)01276-1  0.317
1995 Albin RL. The pathophysiology of chorea/ballism and Parkinsonism. Parkinsonism & Related Disorders. 1: 3-11. PMID 18590996 DOI: 10.1016/1353-8020(95)00011-T  0.329
1995 Albin RL. Selective neurodegeneration in Huntington's disease. Annals of Neurology. 38: 835-6. PMID 8526454 DOI: 10.1002/ana.410380602  0.307
1995 Kaatz KW, Albin RL. Intrastriatal and intrasubthalamic stimulation of metabotropic glutamate receptors: a behavioral and Fos immunohistochemical study. Neuroscience. 66: 55-65. PMID 7637875 DOI: 10.1016/0306-4522(94)00568-P  0.325
1995 Albin RL, Young AB, Penney JB. The functional anatomy of disorders of the basal ganglia. Trends in Neurosciences. 18: 63-4. PMID 7537410 DOI: 10.1016/0166-2236(95)80020-3  0.448
1995 Albin RL, Tagle DA. Genetics and molecular biology of Huntington's disease. Trends in Neurosciences. 18: 11-4. PMID 7535483 DOI: 10.1016/0166-2236(95)93943-R  0.363
1994 Veenman CL, Albin RL, Richfield EK, Reiner A. Distributions of GABAA, GABAB, and benzodiazepine receptors in the forebrain and midbrain of pigeons. The Journal of Comparative Neurology. 344: 161-89. PMID 8077457 DOI: 10.1002/Cne.903440202  0.3
1994 Tallaksen-Greene SJ, Albin RL. Localization of AMPA-selective excitatory amino acid receptor subunits in identified populations of striatal neurons. Neuroscience. 61: 509-19. PMID 7969927 DOI: 10.1016/0306-4522(94)90430-8  0.324
1994 Bazzett TJ, Becker JB, Falik RC, Albin RL. Chronic intrastriatal quinolinic acid produces reversible changes in perikaryal calbindin and parvalbumin immunoreactivity. Neuroscience. 60: 837-41. PMID 7523988 DOI: 10.1016/0306-4522(94)90266-6  0.329
1993 Price RH, Albin RL, Sakurai SY, Polinsky RJ, Penney JB, Young AB. Cerebellar excitatory and inhibitory amino acid receptors in multiple system atrophy. Neurology. 43: 1323-8. PMID 8392149 DOI: 10.1212/WNL.43.7.1323  0.501
1993 Bazzett TJ, Becker JB, Kaatz KW, Albin RL. Chronic intrastriatal dialytic administration of quinolinic acid produces selective neural degeneration. Experimental Neurology. 120: 177-85. PMID 8387931 DOI: 10.1006/exnr.1993.1053  0.336
1993 Jones JM, Albin RL, Feldman EL, Simin K, Schuster TG, Dunnick WA, Collins JT, Chrisp CE, Taylor BA, Meisler MH. mnd2: a new mouse model of inherited motor neuron disease. Genomics. 16: 669-77. PMID 8325640 DOI: 10.1006/Geno.1993.1246  0.336
1993 Sakurai SY, Lutz PL, Schulman A, Albin RL. Unchanged [3H]MK-801 binding and increased [3H]flunitrazepam binding in turtle forebrain during anoxia. Brain Research. 625: 181-5. PMID 8275301 DOI: 10.1016/0006-8993(93)91057-Y  0.301
1993 Strong TV, Tagle DA, Valdes JM, Elmer LW, Boehm K, Swaroop M, Kaatz KW, Collins FS, Albin RL. Widespread expression of the human and rat Huntington's disease gene in brain and nonneural tissues. Nature Genetics. 5: 259-65. PMID 8275091 DOI: 10.1038/Ng1193-259  0.31
1993 Albin RL. Antagonistic pleiotropy, mutation accumulation, and human genetic disease. Genetica. 91: 279-86. PMID 8125276 DOI: 10.1007/BF01436004  0.323
1993 Albin RL, Hollingsworth Z, Sakurai SY, Gilman S. Inhibitory and excitatory amino acid neurotransmitter binding sites in cynomolgus monkey (Macaca fascicularis) cervical spinal cord. Brain Research. 604: 354-7. PMID 8096159 DOI: 10.1016/0006-8993(93)90391-Y  0.451
1993 Kremer B, Tallaksen-Greene SJ, Albin RL. AMPA and NMDA binding sites in the hypothalamic lateral tuberal nucleus: implications for Huntington's disease. Neurology. 43: 1593-5. PMID 7688883 DOI: 10.1212/WNL.43.8.1593  0.378
1992 Kincaid AE, Albin RL, Newman SW, Penney JB, Young AB. 6-Hydroxydopamine lesions of the nigrostriatal pathway alter the expression of glutamate decarboxylase messenger RNA in rat globus pallidus projection neurons. Neuroscience. 51: 705-18. PMID 1488118 DOI: 10.1016/0306-4522(92)90309-P  0.502
1992 Albin RL, Reiner A, Anderson KD, Dure LS, Handelin B, Balfour R, Whetsell WO, Penney JB, Young AB. Preferential loss of striato-external pallidal projection neurons in presymptomatic Huntington's disease. Annals of Neurology. 31: 425-30. PMID 1375014 DOI: 10.1002/Ana.410310412  0.529
1992 Albin RL, Gilman S. GABAA, GABAB, and benzodiazepine binding sites in the cerebellar cortex of the red-eared turtle (Pseudemys scripta). Brain Research. 595: 164-6. PMID 1334769 DOI: 10.1016/0006-8993(92)91469-U  0.464
1992 Tallaksen-Greene SJ, Wiley RG, Albin RL. Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons. Brain Research. 594: 165-70. PMID 1334764 DOI: 10.1016/0006-8993(92)91044-F  0.329
1992 Albin RL, Makowiec RL, Hollingsworth ZR, Dure LS, Penney JB, Young AB. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study. Neuroscience. 46: 35-48. PMID 1317515 DOI: 10.1016/0306-4522(92)90006-N  0.5
1992 Albin RL, Greenamyre JT. Alternative excitotoxic hypotheses. Neurology. 42: 733-8. PMID 1314341 DOI: 10.1212/Wnl.42.4.733  0.577
1991 Albin RL, Makowiec RL, Hollingsworth Z, Sakurai SY, Dure LS, Penney JB, Young AB. Excitatory amino acidergic pathways and receptors in the basal ganglia. Amino Acids. 1: 339-50. PMID 24194174 DOI: 10.1007/BF00814003  0.51
1991 Albin RL, Qin Y, Young AB, Penney JB, Chesselet MF. Preproenkephalin messenger RNA-containing neurons in striatum of patients with symptomatic and presymptomatic Huntington's disease: an in situ hybridization study. Annals of Neurology. 30: 542-9. PMID 1838677 DOI: 10.1002/ana.410300406  0.525
1991 Albin RL, Price RH, Sakurai SY, Penney JB, Young AB. Excitatory and inhibitory amino acid binding sites in human dentate nucleus. Brain Research. 560: 350-3. PMID 1760743 DOI: 10.1016/0006-8993(91)91258-3  0.492
1991 Albin RL, Sakurai SY, Makowiec RL, Gilman S. Excitatory and inhibitory amino acid neurotransmitter binding sites in the cerebellar cortex of the pigeon (Columba livia). Journal of Chemical Neuroanatomy. 4: 429-37. PMID 1685884 DOI: 10.1016/0891-0618(91)90023-6  0.477
1991 Albin RL, Sakurai SY, Makowiec RL, Higgins DS, Young AB, Penney JB. Excitatory amino acid, GABA(A), and GABA(B) binding sites in human striate cortex. Cerebral Cortex (New York, N.Y. : 1991). 1: 499-509. PMID 1668367 DOI: 10.1093/Cercor/1.6.499  0.48
1990 Albin RL, Makowiec RL, Hollingsworth Z, Dure LS, Penney JB, Young AB. Excitatory amino acid binding sites in the periaqueductal gray of the rat. Neuroscience Letters. 118: 112-5. PMID 2175406 DOI: 10.1016/0304-3940(90)90261-7  0.481
1990 Albin RL, Gilman S. Autoradiographic localization of inhibitory and excitatory amino acid neurotransmitter receptors in human normal and olivopontocerebellar atrophy cerebellar cortex. Brain Research. 522: 37-45. PMID 2171714 DOI: 10.1016/0006-8993(90)91574-Z  0.474
1990 Chu DC, Albin RL, Young AB, Penney JB. Distribution and kinetics of GABAB binding sites in rat central nervous system: a quantitative autoradiographic study. Neuroscience. 34: 341-57. PMID 2159128 DOI: 10.1016/0306-4522(90)90144-S  0.495
1990 Makowiec RL, Albin RL, Cha JH, Young AB, Gilman S. Two types of quisqualate receptors are decreased in human olivopontocerebellar atrophy cerebellar cortex. Brain Research. 523: 309-12. PMID 1976026 DOI: 10.1016/0006-8993(90)91504-A  0.585
1990 Albin RL, Reiner A, Anderson KD, Penney JB, Young AB. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia. Annals of Neurology. 27: 357-65. PMID 1972318 DOI: 10.1002/Ana.410270403  0.459
1990 Albin RL, Young AB, Penney JB, Handelin B, Balfour R, Anderson KD, Markel DS, Tourtellotte WW, Reiner A. Abnormalities of striatal projection neurons and N-methyl-D-aspartate receptors in presymptomatic Huntington's disease. The New England Journal of Medicine. 322: 1293-8. PMID 1691447 DOI: 10.1056/Nejm199005033221807  0.555
1989 Albin RL, Aldridge JW, Young AB, Gilman S. Feline subthalamic nucleus neurons contain glutamate-like but not GABA-like or glycine-like immunoreactivity. Brain Research. 491: 185-8. PMID 2569908 DOI: 10.1016/0006-8993(89)90103-0  0.59
1989 Albin RL, Gilman S. Parasagittal zonation of GABA-B receptors in molecular layer of rat cerebellum. European Journal of Pharmacology. 173: 113-4. PMID 2558028 DOI: 10.1016/0014-2999(89)90014-9  0.459
1989 Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends in Neurosciences. 12: 366-75. PMID 2479133 DOI: 10.1016/0166-2236(89)90074-X  0.531
1988 Albin RL, Young AB. Somatosensory phenomena in Huntington's disease. Movement Disorders : Official Journal of the Movement Disorder Society. 3: 343-6. PMID 2974928 DOI: 10.1002/mds.870030411  0.461
1988 Greenamyre JT, Maragos WF, Albin RL, Penney JB, Young AB. Glutamate transmission and toxicity in Alzheimer's disease. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 12: 421-30. PMID 2900537 DOI: 10.1016/0278-5846(88)90102-9  0.652
1988 Young AB, Greenamyre JT, Hollingsworth Z, Albin R, D'Amato C, Shoulson I, Penney JB. NMDA receptor losses in putamen from patients with Huntington's disease. Science (New York, N.Y.). 241: 981-3. PMID 2841762 DOI: 10.1126/Science.2841762  0.652
1988 Albin RL, Young AB, Penney JB. Tetrahydro-9-aminoacridine (THA) interacts with the phencyclidine (PCP) receptor site. Neuroscience Letters. 88: 303-7. PMID 2838771 DOI: 10.1016/0304-3940(88)90228-5  0.475
1988 Reiner A, Albin RL, Anderson KD, D'Amato CJ, Penney JB, Young AB. Differential loss of striatal projection neurons in Huntington disease. Proceedings of the National Academy of Sciences of the United States of America. 85: 5733-7. PMID 2456581 DOI: 10.1073/Pnas.85.15.5733  0.451
Show low-probability matches.